AL-8326

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameAL-8326
Drug Alias NameAL-8326
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsFibroblast growth factor receptors antagonistsSerine/threonine-protein kinase Aurora-B inhibitors
TargetsFibroblast growth factor receptorsVascular endothelial growth factor receptorSerine/threonine-protein kinase Aurora-B
Therapy Area/IndicationsSolid tumoursGenital Neoplasms, FemaleSmall Cell Lung Carcinoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpainMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAdvenchen Laboratories Nanjing LtdHangzhou Aidecheng Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAdvenchen Laboratories LlcAdvenchen Laboratories Nanjing LtdHangzhou Aidecheng Pharmaceutical Technology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursGenital Neoplasms, FemaleSmall Cell Lung Carcinoma +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A